Amgen’s Tepezza granted marketing authorisation in the UK
8th May 2025 Uncategorised 0Teprotumumab approved as first targeted treatment for thyroid eye disease More: Amgen’s Tepezza granted marketing authorisation in the UK Source: News
read more
Teprotumumab approved as first targeted treatment for thyroid eye disease More: Amgen’s Tepezza granted marketing authorisation in the UK Source: News
read more
Study explores whether PI3Kδ targeting could combat resistance More: iOnctura starts randomised phase 1/2 trial in lung cancer treatment Source: News
read moreLess than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a first-line breast cancer trial, the companies have scored again in a phase 3 trial in early breast cancer. More: AstraZeneca, Daiichi Sankyo's
read more
UCB’s developmental treatment may be eligible for patient access More: MHRA grants Promising Innovative Medicine designation to UCB’s DoxTM for TK2d Source: News
read more
Demonstrate your skill and prowess by entering this year’s awards! More: PharmaTimes Clinical Researcher of the Year – The Americas Awards Source: News
read moreXellia Pharmaceuticals, the largest and last maker of key antibiotics APIs in Europe, will shutter its Copenhagen production facility in a move seen as a blow to EU reshoring efforts. More: Xellia to shutter Copenhagen antibiotics plant, dealing a blow
read more© 1994 - 2026 B.M. Pharmaceuticals